Received 28 October 2005/Returned for modification 15 December 2005/Accepted 17 March 2006
|
|
- Terence Pierce
- 5 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, June 2006, p Vol. 44, No /06/$ doi: /jcm Copyright 2006, American Society for Microbiology. All Rights Reserved. An In-House RD1-Based Enzyme-Linked Immunospot Gamma Interferon Assay Instead of the Tuberculin Skin Test for Diagnosis of Latent Mycobacterium tuberculosis Infection Luigi Codecasa, 1 Paola Mantegani, 2 Laura Galli, 2 Adriano Lazzarin, 2,3 Paolo Scarpellini, 2 and Claudio Fortis 2 * Villa Marelli Institute, Lombardy Regional Reference Centre for Tuberculosis, Niguarda Hospital, Milan, Italy 1 ; Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy 2 ; and Vita-Salute San Raffaele University, Milan, Italy 3 Received 28 October 2005/Returned for modification 15 December 2005/Accepted 17 March 2006 Identification of individuals infected with Mycobacterium tuberculosis is essential for the control of tuberculosis (TB). The specificity of the currently used tuberculin skin test (TST) is poor because of the broad antigenic cross-reactivity of purified protein derivative (PPD) with BCG vaccine strains and environmental mycobacteria. Both ESAT-6 and CFP-10, two secretory proteins that are highly specific for M. tuberculosis complex, elicit strong T-cell responses in subjects with TB. Using an enzyme-linked immunospot (ELISPOT) IFN- assay and a restricted pool of peptides derived from ESAT-6 and CFP-10, we have previously demonstrated a high degree of specificity and sensitivity of the test for the diagnosis of TB. Here, 119 contacts of individuals with contagious TB who underwent TST and the ELISPOT IFN- assay were consecutively recruited. We compared the efficacy of the two tests in detecting latent TB infection and defined a more appropriate TST cutoff point. There was little agreement between the tests (k 0.33, P < ): 53% of the contacts with a positive TST were ELISPOT negative, and 7% with a negative TST were ELISPOT positive. Furthermore, respectively 76 and 59% of the ELISPOT-negative contacts responded in vitro to BCG and PPD, suggesting that most of them were BCG vaccinated or infected with nontuberculous mycobacteria. The number of spot-forming cells significantly correlated with TST induration (P < ). Our in-house ELISPOT assay based on a restricted pool of highly selected peptides is more accurate than TST for identifying individuals with latent TB infection and could improve chemoprophylaxis for the control of TB. One-third of the world s population is believed to be latently infected with Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), whose global resurgence, supported by the human immunodeficiency virus type 1 (HIV-1) pandemic and emerging multidrug resistance, underlines the need for new control measures and strategies to make a specific diagnosis and prevent transmission (19). Moreover, continued vigilance against active and latent TB is essential in industrialized countries because of the increased immigration from areas with endemic infection. The compulsory screening of immigrant populations for TB has been proposed as a means of controlling this communicable disease (14, 15) but, although the tuberculin skin test (TST) is the method of choice for detecting latent M. tuberculosis infection (LTBI), it cannot be considered a gold standard because of the number of false-positive and negative reactions, and the variability of their interpretation (1, 2). In particular, the purified protein derivative (PPD) antigen used for the test has broad cross-reactivity with antigens derived from various mycobacterial species, including the vaccine strains of Bacillus Calmette-Guérin (BCG) (1, 2), and false-negative results occur in patients with advanced TB or severe immunodeficiency (10, 25). Another operational drawback of TST is the need for a return visit to allow a reading of the results, and it is worth * Corresponding author. Mailing address: Clinic of Infectious Diseases, San Raffaele Scientific Institute, Via Stamira D Ancona 20, Milano, Italy. Phone: Fax: fortis.claudio@hsr.it. noting that the BCG vaccination of children commonly practiced in most parts of the world reduces its specificity. New in vitro tests based on an ability to detect the gamma interferon (IFN- ) released by activated T lymphocytes have recently been proposed (35). These assays use antigens specific for M. tuberculosis, such as early secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10), which are two low-molecular-mass secretory proteins encoded by genes located within region of difference 1 (RD1) of the M. tuberculosis genome (7, 41). This region is absent in all of the vaccine strains of BCG and in nontuberculous mycobacteria (NTM) with the exception of M. kansasii, M. marinum, and M. szulgai (33). These proteins and the synthetic overlapping peptides corresponding to the full length of each elicit a strong T-cell response in animal models of TB (9, 43) and human with active TB infection (4, 5, 36, 38, 42, 44) or LTBI (11, 18, 29, 30, 37, 39). The QuantiFERON-TB assay (Cellestis Limited, Carnegie, Victoria, Australia) and the T-SPOT TB assay (Oxford Immunotec, Oxford, United Kingdom) are two commercial IFN- assays, and a number of in-house assays have also been assessed (3, 17, 31, 35). Although the sensitivity and specificity of these assays varies across studies, a recent systemic review of the literature (35) has shown (i) that assays based on RD1 antigens are more specific than TST and PPD-based assays, (ii) that cocktails of RD1 antigens offer the best combination of specificity and sensitivity, and (ii) that RD1-based assays detect ca. 80% of individuals with suspected LTBI regardless of their previous BCG vaccination status or infection with NTM. 1944
2 VOL. 44, 2006 IN-HOUSE ASSAY FOR DIAGNOSIS OF LATENT TB INFECTION 1945 Region of origin Country (n) TABLE 1. Demographic characteristics of close contacts enrolled in the study a No. of subjects Median age (yr) Range (yr) No. of subjects aged 15 yr Male/female ratio No. of subjects BCG vaccinated No. of subjects with TST 5 mm No. of subjects receiving chemoprophylaxis Northwest Ethiopia (3) / Africa Morocco (2) 2 Senegal (2) 2 Gambia (1) 1 Algeria (1) 1 Asia Philippines (18) / People s Republic 2 of China (4) Sri Lanka (3) 2 Nepal (2) 2 Indonesia (1) 0 South America Peru (33) / Ecuador (12) 8 East Europe Russia (2) / Ukraine (1) 1 Rumania (1) 1 West Europe Italy (31) / France (1) 0 Spain (1) 0 Total / a Values represent totals or means for each region, except as noted. n, number of subjects by country. We have recently validated an in-house enzyme-linked immunospot assay (ELISPOT) IFN- assay based on a restricted pool of highly selected synthetic peptides derived from ESAT-6 and CFP-10 proteins in a group of HIV-positive or HIV-negative patients with active TB (40). The test was highly specific (87%) and sensitive (93%) and made it possible to distinguish individuals infected with M. tuberculosis from those vaccinated with BCG. We have also compared it with the commercial T-SPOT TB assay that is currently approved for use in Europe and awaiting U.S. Food and Drug Administration approval (27). Eighty-six individuals at high risk for developing TB infection were consecutively recruited from October 2004 to January 2005 and tested under double-blind conditions in separate laboratories. The concordance between the two tests was 98.9% and the fact that only one subject resulted in-house ELISPOT-positive (borderline) but T-SPOT TB negative (P. Mantegani, unpublished data) confirmed the performance of our assay. People who have spent time in close contact with individuals with infectious TB are at the highest risk of infection and TB progression and represent a high priority for testing. For this reason, we recruited a group of household contacts who underwent TST and our in-house ELISPOT assay in the context of a surveillance program. The aims of the study were (i) to assess whether the ELIS POT assay could be used to identify individuals with LTBI and to compare the in vivo (TST) and in vitro (ELISPOT assay) responses to PPD, (ii) to verify whether ELISPOT could help define a TST induration cutoff point that better correlates with a diagnosis of LTBI, and (iii) to verify whether positive responses to the ELISPOT assay correspond to the decision to treat. MATERIALS AND METHODS Participants. Between November 2003 and March 2004, 119 household contacts of contagious (sputum-smear-positive) TB patients were consecutively recruited by the Villa Marelli Institute (the Lombardy Regional Reference Centre for Tuberculosis, Milan, Italy) in the context of a surveillance program, and underwent Mantoux TST and the ELISPOT IFN- assay (12, 40). Their origins and characteristics (age, gender, number of subjects with a TST-positive response or BCG-vaccinated, and number of subjects receiving chemotherapy) are shown in Table 1. The standard TST was performed using five tuberculin units (0.1 ml) of PPD administered intradermally in the volar surface of the forearm by an experienced person, and the size of the induration was evaluated after 48 to 72 h. An X-ray image was obtained for each subject with an induration of 5 mm (a positive reaction), and subjects were considered for latent TB preventive treatment according to the Lombardy regional guidelines adapted from the Centers for Disease Control and Prevention guidelines (Fig. 1) (1, 26). The subjects case histories and previous BCG vaccinations, proved by BCG scar or record, were investigated (bearing in mind that most of the contacts came from countries where BCG vaccination is extensively used at least at birth and that the absence of a scar does not necessarily mean lack of vaccination because not all vaccinated individuals develop a detectable scar). The subjects who were not excluded because of their individual clinical condition or because they refused preventive treatment usually received isoniazid at 5 mg/kg/day for 6 months; those aged 15 years or less were prescribed isoniazid for 2 months regardless of TST positivity and then underwent a repeat test. The subjects with TST induration of 5 mm, underwent a second test after 2 months; if the results were positive, they underwent chest X-ray and were considered for chemoprophylaxis. Ex vivo ELISPOT assay. The ELISPOT IFN- assay was performed as previously described (40). Briefly, cells/well of peripheral blood mononuclear cells (PBMC) were seeded in triplicate in 96-well plates (MAIPS4510; Millipore, Bedford, Mass.) precoated with anti-ifn- capture monoclonal antibody (B-B1; Diaclone, Besançon, France) and stimulated with the different
3 1946 CODECASA ET AL. J. CLIN. MICROBIOL. antigens for 24 h at 37 C in air plus 5% CO 2. Biotinylated anti-ifn- detection monoclonal antibody (B-G1; Diaclone) was added for 4 h, followed by the addition of streptavidin-alkaline phosphatase conjugate (Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany) for 1 h. After a washing step, the nitroblue tetrazolium-bcip (5-bromo-4-chloro-3-indolylphosphate; Sigma, St. Louis, Mo.) chromogenic substrate was added. The individual spots were counted by using an automated image analysis system ELISPOT reader (AID-GmbH, Strassberg, Germany). The responses were scored as positive if the test wells contained a higher mean number of spot-forming cells (SFC) than the mean number plus two standard deviations in the negative control wells, and when the number of SFC per million PBMC in the stimulated wells (minus the values of the negative control wells) was 25 (in our experience with the PBMC of 128 healthy subjects, the mean number of SFC per million PBMC plus two standard deviation was 25 in negative control wells). A pool of five synthetic M. tuberculosis peptides (MTP) with a length of 20 amino acids derived from the sequences of ESAT-6 and CFP-10 proteins were used at a final concentration of 2 g/ml per peptide (10 g/ml in total) for the detection of a specific response. PPD prepared from M. tuberculosis (Statens Serum Institut, Copenhagen, Denmark) and tested at 1 g/ml and heat-inactivated and sonicated whole-cell BCG (Organon Teknika, Boxtel, The Netherlands) were also used. PBMC in medium alone or stimulated with phytohemagglutinin (PHA-P; Sigma) at 25 g/ml were used as negative or positive controls, respectively. Statistical analysis. The data were analyzed by using SAS software (version 8.2; SAS Institute). All of the significance tests were two sided, and a P value of 0.05 was considered to be statistically significant. The differences in the mean number of MTP-specific SFC between individuals classified as 1, 2, or 4 for TB infection (according to the directions of the American Thoracic Society) (2, 40) were tested by using the Kruskal-Wallis test (1 versus 2 versus 4) or the two-sample Wilcoxon rank sum test (1 versus 2 to 4) for nonparametric data. McNemar s test of symmetry for paired data was used to test the equality of the off-diagonal frequencies obtained when we compared two different methods for assessing TB positivity (TST, ELISPOT-MTP, ELISPOT-PPD, and ELISPOT-BCG). The agreement of the different TB classification tests was assessed by estimating Cohen s Kappa (k) statistic (and the corresponding 95% confidence interval [CI]). According to Fleiss, k values of 0.75 suggest excellent agreement beyond that determined by chance; values of 0.4 and 0.75 indicate fair to good agreement, and values of 0.4 indicate poor agreement (22). The receiver-operating-characteristics curve was calculated to measure the ability of the TST to classify correctly ELISPOT-MTP-positive and -negative individuals (measured on the basis of the area under the curve [AUC]) and to identify the optimal TST cutoff point that minimized classification errors. FIG. 1. TB screening flowchart and management of close contacts. RESULTS Frequencies of ELISPOT-MTP responses in relation to TST reactivity. At screening, 42 of the 119 prospectively recruited close contacts (35%) had a negative TST response, and 77 (65%, including 7 with a documented previous TB infection) had a positive response. A total of 41 (53%) of the 77 TST-positive contacts did not respond to MTP in the ELISPOT (ELISPOT-MTP) assay, and 3 of 42 (7%) TST-negative contacts were ELISPOT-MTP positive (2 with a positive and 1 with a negative response to ELISPOT-PPD; all three responded to ELISPOT-BCG) (Fig. 2). It is worth noting that a second TST repeated after 2 months in the two ELISPOT-PPD positive subjects was still negative. The test of symmetry was highly significant (P ) and the agreement of ELISPOT-MTP assay and TST reactivity was quite small (k 0.328; 95% CI to 0.459). Of the 42 TST-negative contacts (93%; 95% CI 82 to 97), 39 were also ELISPOT-MTP negative, whereas 36 of the 77 TST-positive contacts (47%; 95% CI 44 to 51) were also ELISPOT-MTP positive. All seven TST-positive contacts with documented previous TB infection responded to ELISPOT-MTP. When tested, the contagious index cases were positive to ELISPOT- MTP, ELISPOT-BCG, and ELISPOT-PPD (data not shown). Of the 80 ELISPOT-MTP-negative contacts, 4 were borderline (SFC 10 6 PBMC 22.5): 3 with TST indurations of 10 mm and a positive ELISPOT-PPD and 1 with a negative response to PPD in vivo (TST) and in vitro (ELISPOT). Frequencies of ELISPOT-MTP responses in relation to ELISPOT-BCG responses. Of the 119 contacts, 100 (84%) responded to ELISPOT-BCG (27 TST negative and 73 TST positive). All 39 ELISPOT-MTP positive contacts also responded to BCG, whereas 61 of 80 ELISPOT-MTP negative contacts (76%) were ELISPOT-BCG positive, suggesting that most of them should be vaccinated or infected with an NTM (Fig. 2 and Table 1). In fact, 44 of 67 (66%) individuals in
4 VOL. 44, 2006 IN-HOUSE ASSAY FOR DIAGNOSIS OF LATENT TB INFECTION 1947 FIG. 2. TST, ELISPOT-MTP, and ELISPOT-BCG results in close contacts. ELISPOT-MTP, ELISPOT assay using the pool of M. tuberculosis specific peptides (MTP) as an antigen; ELISPOT-BCG, ELISPOT assay using BCG as an antigen. which a BCG scar was present did not respond to ELISPOT- MTP, but all responded to ELISPOT-BCG. The test of symmetry was highly significant (P ), and the agreement between ELISPOT-MTP and ELISPOT-BCG was small (k 0.169; 95% CI to 0.251). Frequencies of ELISPOT-MTP responses in relation to ELISPOT-PPD responses. When we analyzed the response frequencies to ELISPOT-PPD in 106 of 119 contacts in relation to ELISPOT-MTP, 30 of the 31 ELISPOT-MTP positive contacts (97%; 95% CI 86 to 99) also responded to PPD (the only nonresponder was TST negative but ELISPOT-BCG positive), whereas 44 of 75 ELISPOT-MTP negative contacts (59%) responded to ELISPOT-PPD (Table 2). This result corroborates the data that many contacts were vaccinated. The test of symmetry was once again highly significant (P ), and the agreement between the ELISPOT-MTP response and the ELISPOT-PPD was small (k 0.271; 95% CI to 0.388). Frequencies of ELISPOT-PPD responses in relation to TST reactivity. Of the 67 TST-positive contacts, 61 (91%; 95% CI 85 to 95) had a positive ELISPOT-PPD result, and 6 (9%) a negative ELISPOT-PPD result (three responders and three nonresponders to BCG; all nonresponders to MTP) (Table 3). Moreover, 13 of 39 TST-negative contacts (33%) responded to ELISPOT-PPD (11 of whom did not respond to MTP), thus demonstrating that the ELISPOT assay is more sensitive than the TST. In this case, the test of symmetry was not significant, and the agreement between the ELISPOT-PPD response and TST reactivity was quite high (k 0.6; 95% CI 0.44 to 0.76). Correlation of ELISPOT-MTP responses with TB classification and TST induration size. When the contacts were grouped by TB classification (2), there was a significant between-class difference in the mean number of SFC, with the highest values being observed in class 4 (Fig. 3). Likewise, there was a significant difference (P ) in TST induration between the contacts with a negative or positive ELIS POT-MTP response (Fig. 4). Analysis of the ability of TST induration to discriminate negative and positive ELISPOT-MTP responses revealed an AUC of 85% (95% CI 77 to 92%; P ) and showed that the best cutoff point was 12.5 mm. When TST reactivity was defined on the basis of an induration cutoff point of 10 mm, 13 subjects changed from positive to negative, thus making the TST-positive and ELISPOT-MTP negative responses 28 of 64 (44%) instead of the initial 41 of 77 (53%; Fig. 2). Correspondence between ELISPOT-MTP responses and decision to treat. The majority of the TST-positive contacts (62 of 83 [75%]) received preventive chemoprophylaxis for latent TB infection; 57 of the 119 contacts (17 with a positive TST) were not treated (Table 1 and Fig. 1). Positive ELISPOT-MTP results were significantly more frequent among the treated (27 of 62 [44%]) than the untreated contacts (12 of 57 [21%]), but ELISPOT-MTP result TABLE 2. Frequencies of ELISPOT-PPD responses in relation to ELISPOT-MTP responses No. (%) of responses that were ELISPOT-PPD: Negative Positive Negative 31 (41) 44 (59) Positive 1 (3) 30 (97) TST result TABLE 3. Frequencies of ELISPOT-PPD responses in relation to TST reactivity Negative No. (%) of responses that were ELISPOT-PPD: Positive Negative 26 (67) 13 (33) Positive 6 (9) 61 (91)
5 1948 CODECASA ET AL. J. CLIN. MICROBIOL. FIG. 3. Box-and-whisker plot of the SFC per million PBMC (minus the values of the negative control wells) in relation to TB classification. The boxes indicate the median, the 25th and 75th quartiles, and the minimum and maximum values. The groups were compared by using the Kruskal-Wallis test (P ). 56% (35 of 62) of the treated contacts had negative ELISPOT- MTP results. DISCUSSION The results of this study show that our in-house ELISPOT IFN- assay, which uses a restricted and highly selected pool of synthetic peptides derived from ESAT-6 and CFP-10 proteins, is more accurate in identifying subjects with suspected LTBI (close contacts of people with contagious TB) than either the TST or the ELISPOT-PPD assay. Furthermore, on the basis of ELISPOT-MTP responses, we have been able to define a TST induration cutoff point that better correlates with LTBI. The large majority of the recruited contacts (86 of 119) came from countries where M. tuberculosis and NTM are endemic and BCG vaccination is a common practice (in 67 of them it was possible to document the BCG vaccination). They therefore represent a high-risk population in whom it is particularly difficult to diagnose M. tuberculosis infection because the specificity of the TST routinely used to detect it is low as a result of the cross-reaction of PPD with vaccine BCG strains and NTM (1, 2). For this reason, new strategies for specific diagnosis and prevention of transmission are mandatory. The agreement between TST reactions and in-house ELIS POT-MTP responses was quite small: 53% of the TST-positive subjects did not respond to ELISPOT-MTP. The specificity of the ELISPOT-MTP assay was confirmed by the fact that 100% of the ELISPOT-MTP positive subjects were ELISPOT-BCG positive and 97% were ELISPOT-PPD positive. Conversely, the fact that 76% of the ELISPOT-MTP negative subjects were ELISPOT-BCG positive and 59% were ELISPOT-PPD positive supports the idea that most contacts may be vaccinated (Table 1) or NTM infected, thus underlining the greater sensitivity of the ELISPOT assay over the TST, as has also been reported by others (20, 28, 32, 34). Of note, 44 of the 67 individuals with a documented BCG scar were ELISPOT-MTP negative but ELISPOT-BCG positive. In a previous study, we FIG. 4. Box-and-whisker plot of TST induration (in mm) in relation to ELISPOT-MTP response (negative or positive). The boxes indicate the median, the 25th and 75th quartiles, and minimum and maximum values. found a smaller number of individuals who were ELISPOT- MTP negative and ELISPOT-BCG positive (63%), but most of the subjects involved were native Italians, and Italy has a low incidence of TB and BCG vaccination is not compulsory (40). Furthermore, the close relationship between the size of the TST induration and the ELISPOT-MTP response (Fig. 4) may explain the large number of subjects who were ELISPOT negative and TST positive. It is worth noting that 3 of the 42 TST-negative contacts were ELISPOT-MTP positive (including 2 aged less than 15 years whose second TST after 2 months of chemoprophylaxis were still negative). It has been reported that a discordance between in vivo (TST) and in vitro (ELISPOT assay) responses to PPD may be due to a specific cutaneous anergy caused by oral BCG vaccinations in spite of significant increases in mycobacterium-specific IFN- responses in PBMC (24); such an anergy also occurs in ca. 15% of patients with active pulmonary disease, thus giving rise to false-negative TST results (8, 24). The agreement between TST and ELISPOT-PPD responses was quite high: 91% of the subjects were positive in both tests, and only 9% were TST positive and ELISPOT-PPD negative. However, 33% of the TST-negative contacts responded in vitro to PPD. These results are consistent with the greater sensitivity of ELISPOT-PPD over the TST, as previously reported (21, 23, 35). One advantage of the ELISPOT assay is the possibility of evaluating IFN- production at the single-cell level (expressed as the number of SFC). In this regard, we observed a close relationship between the number of SFC and the TB classification, with the highest values being found in individuals with a documented history of TB infection (class 4). This substantially shows that the greater the exposure to M. tuberculosis, the greater the response to ELISPOT-MTP (20, 39). It is possible that this quantitative parameter could be used to discriminate acute infection from LTBI, but this needs to be demonstrated in larger-scale longitudinal studies. When the ability of the TST to discriminate negative and
6 VOL. 44, 2006 IN-HOUSE ASSAY FOR DIAGNOSIS OF LATENT TB INFECTION 1949 positive responses to ELISPOT-MTP was tested by means of the receiver-operating-characteristics curve, the AUC was 85% and the best cutoff point about 12.5 mm of induration (near the conventional 10-mm threshold). This suggests that a TST reaction should be considered positive when the induration is 10 mm (and not 5 mm as is now done) also in close contacts originating from countries with a high prevalence of TB (1, 26). Using this area of induration as a new cutoff point, 44% of the contacts (as against the initial 53%) were determined to be TST positive and ELISPOT-MTP negative. However, even after this correction, the diagnostic sensitivity of our in-house ELISPOT assay was greater than that of the TST. The definition of positive or negative responses to ELISPOT assays is still empirical, even if a general consent on how to consider positive results exists in the literature. On the basis of our previously reported criteria (40), 4 of 80 contacts with a negative ELISPOT-MTP response were borderline (22.5 SFC per million PBMC, minus the values of the negative control wells); since 3 of these had a TST induration of 10 mm and were ELISPOT-PPD positive, a cutoff point of 20 SFC per 10 6 PBMC may better define positivity at least in close contacts. Finally, 75% of the contacts with a positive TST reaction (after the first and second test) received preventive treatment; 20% refused or were ruled out because of their individual clinical condition. This is a real problem for any program aimed at preventing and/or controlling the spread of TB. It is interesting that 56% of the treated individuals were ELISPOT- MTP negative and that 21% of the untreated individuals were ELISPOT-MTP positive. If we also consider the technical problems relating to the execution and reading of the TST, and the need for a return visit, it can be said that the new generation of ELISPOT IFN- assays based on a cocktail of RD1- restricted peptides offer a real advantage over TST by better targeting interventions against latent TB to truly infected individuals and by helping to avoid unnecessary treatment. Cost may be a limiting factor (we have calculated a cost of approximately US$6] on a per-patient basis for disposables and reagents) but, given the improved targeting of chemoprophylaxis, the ELISPOT assay could be very cost-effective in the long term. Moreover, the restricted number of highly selected peptides used in our assay further reduces its cost. The possibility of false-negative ELISPOT IFN- results and the consequent underestimate of LTBI cannot be excluded mainly because of human leukocyte antigen restrictions, especially when a limited number of peptides are used (28). However, this possibility can be at least partially excluded because of the highly sensitive nature of our test (40) and by the comparison with the commercial T-SPOT TB assay. In future studies, we plan to test individuals with acute or LTBI, either HIV positive or negative, from South Africa and Uganda countries. At the moment, it is difficult to envisage a wide-scale application of the ELISPOT methodology in low-resource countries where TB infection is endemic due to ELISPOT s difficulties in discriminating acute from latent infection. However, due to the increasing migration of peoples from these countries to industrialized ones, this methodology may be better designed for screening immigrants (especially close contacts of individuals with acute TB infection) (13, 16). The ELISPOT assay may also allow a more sensitive testing of healthcare workers discriminating truly infected people from BCG-vaccinated subjects or from subjects with nonspecific TST reactions (e.g., hypersensitivity to heterologous proteins) (6). However, before abandoning TST as the reference standard, long-term longitudinal studies are required in order to determine the association between positive ELISPOT responses and the subsequent risk of active TB. ACKNOWLEDGMENTS We are very grateful to all of the study participants. This study was partially funded by the Italian Ministry of Health (RF04-126). REFERENCES 1. American Thoracic Society Targeted tuberculin testing and treatment of latent tuberculosis infection. Joint statement of the American Thoracic Society and the Centers for Disease Control and Prevention, endorsed by the Council of the Infectious Diseases Society of America in September Am. J. Respir. Crit. Care Med. 161:S221 S American Thoracic Society Diagnostic standards and classification of tuberculosis in adults and children. Joint statement of the American Thoracic Society and the Centers for Disease Control and Prevention, endorsed by the Council of the Infectious Diseases Society of America in September Am. J. Respir. Crit. Care Med. 161: Andersen, P., M. E. Munk, J. M. Pollock, and T. M. Doherty Specific immune-based diagnosis of tuberculosis. Lancet 356: Arend, S. M., P. Andersen, K. E. van Meijgaarden, R. L. Skjot, Y. W. Subronto, J. T. van Dissel, and T. H. Ottenhoff Detection of active tuberculosis infection by T-cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J. Infect. Dis. 181: Arend, S. M., A. Geluk, K. E. van Meijgaarden, J. T. van Dissel, M. Theisen, P. Andersen, and T. H. Ottenhoff Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect. Immun. 68: Askenase, P. W., and J. E. Atwood Basophils in tuberculin and Jones- Mote delayed reactions of humans. J. Clin. Investig. 58: Berthet, F. X., P. B. Rasmussen, I. Rosenkrands, P. Andersen, and B. Gicquel A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 144(Pt. 11): Boussiotis, V. A., E. Y. Tsai, E. J. Yunis, S. Thim, J. C. Delgado, C. C. Dascher, A. Berezovskaya, D. Rousset, J. M. Reynes, and A. E. Goldfeld IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Investig. 105: Brandt, L., T. Oettinger, A. Holm, A. B. Andersen, and P. Andersen Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 157: Caiaffa, W. T., N. M. Graham, N. Galai, R. T. Rizzo, K. E. Nelson, and D. Vlahov Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch. Intern. Med. 155: Chapman, A. L., M. Munkanta, K. A. Wilkinson, A. A. Pathan, K. Ewer, H. Ayles, W. H. Reece, A. Mwinga, P. Godfrey-Faussett, and A. Lalvani Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16: Codecasa, L. R., and G. Besozzi Acceptance of isoniazid preventive treatment by close contacts of tuberculosis cases: a 692-subject Italian study. Int. J. Tuberc. Lung Dis. 2: Cohen, T., and M. Murray Incident tuberculosis among recent US immigrants and exogenous reinfection. Emerg. Infect. Dis. 11: Coker, R Compulsory screening of immigrants for tuberculosis and HIV. BMJ 328: Coker, R. J., A. Bell, R. Pitman, A. Hayward, and J. Watson Screening programmes for tuberculosis in new entrants across Europe. Int. J. Tuberc. Lung Dis. 8: DeAngelis, C. D., and A. Flanagin Tuberculosis: a global problem requiring a global solution. JAMA 293: Dockrell, H. M., and R. E. Weir Whole blood cytokine assays: a new generation of diagnostic tests for tuberculosis? Int. J. Tuberc. Lung Dis. 2: Doherty, T. M., A. Demissie, J. Olobo, D. Wolday, S. Britton, T. Eguale, P. Ravn, and P. Andersen Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40: Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione
7 1950 CODECASA ET AL. J. CLIN. MICROBIOL. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: Ewer, K., J. Deeks, L. Alvarez, G. Bryant, S. Waller, P. Andersen, P. Monk, and A. Lalvani Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: Fietta, A., F. Meloni, A. Cascina, M. Morosini, C. Marena, P. Troupioti, P. Mangiarotti, and L. Casali Comparison of a whole-blood interferongamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am. J. Infect. Control. 31: Fleiss, J Statistical methods for rates and proportions, 2nd ed. John Wiley & Sons, Inc., New York, N.Y. 23. Hill, P. C., R. H. Brookes, A. Fox, K. Fielding, D. J. Jeffries, D. Jackson- Sillah, M. D. Lugos, P. K. Owiafe, S. A. Donkor, A. S. Hammond, J. K. Otu, T. Corrah, R. A. Adegbola, and K. P. McAdam Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin. Infect. Dis. 38: Hoft, D. F., R. M. Brown, and R. B. Belshe Mucosal bacille calmette- Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin. Infect. Dis. 30(Suppl. 3):S217 S Huebner, R. E., M. F. Schein, and J. B. Bass, Jr The tuberculin skin test. Clin. Infect. Dis. 17: Jasmer, R. M., P. Nahid, and P. C. Hopewell Clinical practice. Latent tuberculosis infection. N. Engl. J. Med. 347: Lalvani, A Spotting latent infection: the path to better tuberculosis control. Thorax 58: Lalvani, A., P. Nagvenkar, Z. Udwadia, A. A. Pathan, K. A. Wilkinson, J. S. Shastri, K. Ewer, A. V. Hill, A. Mehta, and C. Rodrigues Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J. Infect. Dis. 183: Lalvani, A., A. A. Pathan, H. Durkan, K. A. Wilkinson, A. Whelan, J. J. Deeks, W. H. Reece, M. Latif, G. Pasvol, and A. V. Hill Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357: Lalvani, A., A. A. Pathan, H. McShane, R. J. Wilkinson, M. Latif, C. P. Conlon, G. Pasvol, and A. V. Hill Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am. J. Respir. Crit. Care Med. 163: Lein, A. D., and C. F. Von Reyn In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. Am. J. Med. Sci. 313: Liebeschuetz, S., S. Bamber, K. Ewer, J. Deeks, A. A. Pathan, and A. Lalvani Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364: Mahairas, G. G., P. J. Sabo, M. J. Hickey, D. C. Singh, and C. K. Stover Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178: Pai, M., K. Gokhale, R. Joshi, S. Dogra, S. Kalantri, D. K. Mendiratta, P. Narang, C. L. Daley, R. M. Granich, G. H. Mazurek, A. L. Reingold, L. W. Riley, and J. M. Colford, Jr Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 293: Pai, M., L. W. Riley, and J. M. Colford, Jr Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4: Pathan, A. A., K. A. Wilkinson, P. Klenerman, H. McShane, R. N. Davidson, G. Pasvol, A. V. Hill, and A. Lalvani Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J. Immunol. 167: Ravn, P., A. Demissie, T. Eguale, H. Wondwosson, D. Lein, H. A. Amoudy, A. S. Mustafa, A. K. Jensen, A. Holm, I. Rosenkrands, F. Oftung, J. Olobo, F. von Reyn, and P. Andersen Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179: Ravn, P., M. E. Munk, A. B. Andersen, B. Lundgren, J. D. Lundgren, L. N. Nielsen, A. Kok-Jensen, P. Andersen, and K. Weldingh Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin. Diagn. Lab. Immunol. 12: Richeldi, L., K. Ewer, M. Losi, B. M. Bergamini, P. Roversi, J. Deeks, L. M. Fabbri, and A. Lalvani T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am. J. Respir. Crit. Care Med. 170: Scarpellini, P., S. Tasca, L. Galli, A. Beretta, A. Lazzarin, and C. Fortis Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection. J. Clin. Microbiol. 42: Sorensen, A. L., S. Nagai, G. Houen, P. Andersen, and A. B. Andersen Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 63: Ulrichs, T., P. Anding, S. Porcelli, S. H. Kaufmann, and M. E. Munk Increased numbers of ESAT-6- and purified protein derivative-specific gamma interferon-producing cells in subclinical and active tuberculosis infection. Infect. Immun. 68: van Pinxteren, L. A., P. Ravn, E. M. Agger, J. Pollock, and P. Andersen Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin. Diagn. Lab. Immunol. 7: Wilkinson, K. A., R. J. Wilkinson, A. Pathan, K. Ewer, M. Prakash, P. Klenerman, N. Maskell, R. Davies, G. Pasvol, and A. Lalvani Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin. Infect. Dis. 40:
Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN-γ Assay for the Diagnosis of Mycobacterium tuberculosis Infection
Original Research Clinical Medicine & Research Volume 4, Number 4:266-272 2006 Marshfield Clinic http://www.clinmedres.org Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN-γ Assay for the
More informationProspective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis-specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Apr. 2005, p. 491 496 Vol. 12, No. 4 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.4.491 496.2005 Copyright 2005, American Society for Microbiology. All Rights
More informationUSE OF A T-CELL BASED TEST FOR DETECTION OF TB INFECTION AMONG IMMUNOCOMPROMISED PATIENTS
ERJ Express. Published on March 15, 2006 as doi: 10.1183/09031936.06.00110205 USE OF A T-CELL BASED TEST FOR DETECTION OF TB INFECTION AMONG IMMUNOCOMPROMISED PATIENTS Piana Federica 1-2, Codecasa Luigi
More informationReview. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis
Interferon- assays for tuberculosis diagnosis Review Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review Madhukar Pai, Lee W Riley, and John M Colford Jr A major challenge in
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationComparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts
Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts Inger Brock, Karin Weldingh, Troels Lillebaek, Frank Follmann, and Peter Andersen Department of Infectious Disease
More informationEffect of tuberculin skin testing on a Mycobacterium tuberculosisspecific
ERJ Express. Published on January 10, 2007 as doi: 10.1183/09031936.00117506 Effect of tuberculin skin testing on a Mycobacterium tuberculosisspecific IFN-γ assay Eliane M.S. Leyten 1, Corine Prins 1,
More informationChapter 6. Discrepancy between Mycobacterium tuberculosis-specific interferon-γ release assays using short versus prolonged in vitro incubation
Discrepancy between Mycobacterium tuberculosis-specific interferon-γ release assays using short versus prolonged in vitro incubation Eliane M.S. Leyten 1,#, Sandra M Arend 1, Corine Prins 1, Frank G. J.
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationReceived 13 December 2004/Returned for modification 18 January 2005/Accepted 24 January 2005
JOURNAL OF CLINICAL MICROBIOLOGY, May 2005, p. 2070 2074 Vol. 43, No. 5 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.5.2070 2074.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationDiscrepancy between Mycobacterium tuberculosis-specific Gamma Interferon Release Assays Using Short and Prolonged In Vitro Incubation
CLINICAL AND VACCINE IMMUNOLOGY, July 2007, p. 880 885 Vol. 14, No. 7 1556-6811/07/$08.00 0 doi:10.1128/cvi.00132-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Discrepancy
More informationPerformance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children
616 TUBERCULOSIS Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children T G Connell*, N Curtis*, S C Ranganathan, J P Buttery...
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationORIGINAL ARTICLE /j x. and 3 Department of Internal Medicine, University of Tor Vergata, Rome, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01391.x Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study D. Goletti 1,2, S. Carrara
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationComparison of Tuberculin Skin test and Quantiferon immunological assay for latent Tuberculosis infection
Monaldi Arch Chest Dis 2005; 63: 3, 158-162 TB CORNER Comparison of Tuberculin Skin test and Quantiferon immunological assay for latent Tuberculosis infection L.R. Codecasa 1, M. Ferrarese 1, V. Penati
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationReceived 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007
CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 714 719 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of
More informationSponsored document from The Journal of Infection
Sponsored document from The Journal of Infection Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice Sarah Gooding a,e, Oni Chowdhury a,e, Tim
More informationTuberculosis (TB) is an important global health problem. A
Monitoring of Peptide-Specific and Gamma Interferon-Productive T Cells in Patients with Active and Convalescent Tuberculosis Using an Enzyme-Linked Immunosorbent Spot Assay Fang-Fang Yang, a Zhi-Quan Tu,
More informationPulmonary Perspective
Pulmonary Perspective An Update on the Diagnosis of Tuberculosis Infection Luca Richeldi Respiratory Disease Clinic, Department of Oncology, Hematology, and Respiratory Disease, University of Modena and
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationImpact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice
Journal of Infection (2007) 54, e169ee174 www.elsevierhealth.com/journals/jinf CASE REPORT Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationReproducibility of QuantiFERON-TB Gold In-Tube Assay
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2008, p. 425 432 Vol. 15, No. 3 1556-6811/08/$08.00 0 doi:10.1128/cvi.00398-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Reproducibility
More informationTitle: Comparison of an ESAT-6/ CFP-10 Peptide-Based ELISPOT Assay to Tuberculin. Skin Test for Tuberculosis Screening in a Moderate Risk Population
CVI Accepts, published online ahead of print on 18 April 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationClinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,
More informationComparison of Sensitivities of Two Commercial Gamma Interferon Release Assays for Pulmonary Tuberculosis
JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 1935 1940 Vol. 46, No. 6 0095-1137/08/$08.00 0 doi:10.1128/jcm.02403-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Comparison
More informationSpecific Detection of Tuberculosis Infection An Interferon- based Assay Using New Antigens
Specific Detection of Tuberculosis Infection An Interferon- based Assay Using New Antigens Toru Mori, Mitsunori Sakatani, Fumio Yamagishi, Tetsuya Takashima, Yoshiko Kawabe, Keiji Nagao, Eriko Shigeto,
More informationTB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
More informationReceived 15 August 2003/Returned for modification 6 November 2003/Accepted 26 January 2004
INFECTION AND IMMUNITY, May 2004, p. 2574 2581 Vol. 72, No. 5 0019-9567/04/$08.00 0 DOI: 10.1128/IAI.72.5.2574 2581.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Evaluation
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationWhat is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries?
REVIEW What is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries? Peter Daley & Poorvi Chordia Author for correspondence Department of Medicine Unit
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationIndeterminate test results of T-SPOT TM.TB performed under routine field conditions
Eur Respir J 2008; 31: 842 846 DOI: 10.1183/09031936.00117207 CopyrightßERS Journals Ltd 2008 Indeterminate test results of T-SPOT TM.TB performed under routine field conditions P. Beffa*, A. Zellweger
More informationUse of Antibodies in Lymphocyte Secretions for Detection of Subclinical Tuberculosis Infection in Asymptomatic Contacts
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1022 1027 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1022 1027.2004 Copyright 2004, American Society for Microbiology. All
More informationDiagnosis of Central Nervous System Tuberculosis by T-Cell-Based Assays on Peripheral Blood and Cerebrospinal Fluid Mononuclear Cells
CLINICAL AND VACCINE IMMUNOLOGY, Sept. 2008, p. 1356 1362 Vol. 15, No. 9 1556-6811/08/$08.00 0 doi:10.1128/cvi.00040-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Diagnosis
More informationCOMPARISON OF TWO INTERFERON-G ASSAYS AND
3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van
More informationThe use of the tuberculin skin test (TST) to diagnose
Annals of Internal Medicine Article Prognostic Value of a T-Cell Based, Interferon- Biomarker in Children with Tuberculosis Contact Mustafa Bakir, MD; Kerry A. Millington, DPhil; Ahmet Soysal, MD; Jonathan
More informationDiagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis
Clin. Lab. 2014;60:1865-1870 Copyright ORIGINAL ARTICLE Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis XUEQIONG WU 1, *, YUANZHENG MA 2, *, LAN WANG 1, DAWEI LI 2, YOURONG YANG 1,
More informationRapid immunodiagnostic assays for Mycobacterium Tuberculosis infection
Vol.2, No.3, 171-176 (2010) Health doi:10.4236/health.2010.23025 Rapid immunodiagnostic assays for Mycobacterium Tuberculosis infection Roba M. Talaat 1*, Gamal S. Radwan 2, Abdelaziz A. Mosaad 3, Saleh
More informationX/01/$ DOI: /CDLI Copyright 2001, American Society for Microbiology. All Rights Reserved.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2001, p. 1089 1096 Vol. 8, No. 6 1071-412X/01/$04.00 0 DOI: 10.1128/CDLI.8.6.1089 1096.2001 Copyright 2001, American Society for Microbiology. All Rights
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationDiagnosis of Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Mar. 2000, p. 155 160 Vol. 7, No. 2 1071-412X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Diagnosis of Tuberculosis
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationª 2005 Lippincott Williams & Wilkins Curr Opin Pulm Med 11: ª 2005 Lippincott Williams & Wilkins.
Utility of the antigen-specific interferon-g assay for the management of tuberculosis Keertan Dheda a,b, Zarir F. Udwadia c, Jim F. Huggett a, Margaret A. Johnson b and Graham A.W. Rook a Purpose of review
More informationPrevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia
RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationEvaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1089 1093 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1089 1093.2004 Copyright 2004, American Society for Microbiology. All
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationImmediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2672 2676 Vol. 48, No. 8 0095-1137/10/$12.00 doi:10.1128/jcm.00482-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Immediate Incubation
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationUse in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study Giovanni Ferrara, Monica Losi, Roberto D Amico, Pietro Roversi,
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationDiagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients
CLINICAL RESEARCH STUDY Diagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients Sung-Han Kim, MD, a,b,c Kyoung-Ho Song, MD, a Su-Jin Choi, MS, b Hong-Bin
More informationTuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release assay
Eur Respir J 29; 34: 1423 1428 DOI: 1.1183/931936.5389 CopyrightßERS Journals Ltd 29 Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release
More informationDiagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test?
Nephrol Dial Transplant (2012) 27: 1645 1650 doi: 10.1093/ndt/gfr516 Advance Access publication 19 September 2011 Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay
More informationCurr Opin Pulm Med 15: ß 2009 Wolters Kluwer Health Lippincott Williams & Wilkins
T-cell interferon-g release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings Keertan Dheda a,b,c, Richard van Zyl Smit a, Motasim Badri a and
More informationSpecific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection
JOURNAL OF CLINICAL MICROBIOLOGY, June 2004, p. 2379 2387 Vol. 42, No. 6 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.6.2379 2387.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationSilicotic subjects are at a high risk of. Comparison of T-Spot.TB and tuberculin skin test among silicotic patients
Eur Respir J 2008; 31: 266 272 DOI: 10.1183/09031936.00054707 CopyrightßERS Journals Ltd 2008 Comparison of T-Spot.TB and tuberculin skin test among silicotic patients C.C. Leung*, W.C. Yam #, W.W. Yew
More informationRapid Diagnosis of Smear-negative Tuberculosis by Bronchoalveolar Lavage Enzyme-linked Immunospot
Rapid Diagnosis of Smear-negative Tuberculosis by Bronchoalveolar Lavage Enzyme-linked Immunospot Claudia Jafari, Martin Ernst, Barbara Kalsdorf, Ulf Greinert, Roland Diel, Detlef Kirsten, Kathleen Marienfeld,
More informationSince its development more than a century ago, the tuberculin
CJASN epress. Published on October 18, 2006 as doi: 10.2215/CJN.01280406 Detecting Latent Tuberculosis Infection in Hemodialysis Patients: A Head-to-Head Comparison of the T-SPOT.TB Test, Tuberculin Skin
More informationJournal of Infectious Diseases Advance Access published August 2, 2013
Journal of Infectious Diseases Advance Access published August 2, 2013 1 Reversion and Conversion of Interferon-gamma Release Assay Results in HIV-1 Infected Individuals Maximilian C. Aichelburg 1,*, Thomas
More informationTuberculin Skin Testing and In Vitro T Cell Responses to ESAT-6 and Culture Filtrate Protein 10 after Infection with Mycobacterium marinum
1797 Tuberculin Skin Testing and In Vitro T Cell Responses to ESAT-6 and Culture Filtrate Protein 10 after Infection with Mycobacterium marinum or M. kansasii Sandra M. Arend, 1 Krista E. van Meijgaarden,
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationThe tuberculin skin test (TST) was formerly the only. Review
Annals of Internal Medicine Review Systematic Review: T-Cell based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update Madhukar Pai, MD, PhD; Alice Zwerling, MSc; and Dick Menzies, MD,
More informationTitle: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
Author's response to reviews Title: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study Authors: Delia Goletti (d.goletti@tiscali.it)
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized
More informationDiagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs)
Diagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs) Educational aims To provide an overview of interferon- release assays (IGRAs) used for detection of tuberculosis
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTable 9. Policy for Tuberculosis Surveillance and Screening
Policy for Tuberculosis Surveillance and Screening Purpose: to identify active cases of tuberculosis or latent TB among residents and staff of the nursing home in order to prevent transmission in this
More informationQuantiFERON-TB Gold and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Children
IJMS Vol 40, No 5, September 2015 Original Article QuantiFERON-TB Gold and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Children Hossein Masoumi Asl 1, MD, MPH; Abdolvahab
More informationInterpretation of tuberculin skin-test results in the diagnosis of tuberculosis in children.
Interpretation of tuberculin skin-test results in the diagnosis of tuberculosis in children. Julius P Kiwanuka Mbarara University of Science and Technology, Mbarara, Uganda ABSTRACT Introduction: The tuberculin
More informationDiagnosis of Active Tuberculosis in China Using an In-House Gamma Interferon Enzyme-Linked Immunospot Assay
CLINICAL AND VACCINE IMMUNOLOGY, June 2009, p. 879 884 Vol. 16, No. 6 1556-6811/09/$08.00 0 doi:10.1128/cvi.00044-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Diagnosis of
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationInterferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients
Interferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients Kevin L. Winthrop,* Melissa Nyendak, Helene Calvet, Peter Oh, Melanie Lo, Gwendolyn Swarbrick,
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationRespiratory Research. Open Access. Abstract. BioMed Central
Respiratory Research BioMed Central Research Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study Delia
More informationEl futuro del diagnostico de la ITL. en tiempos de crisis. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases
El futuro del diagnostico de la ITL. en tiempos de crisis Taller de TB de Barcelona, Noviembre 2012 Professor Ajit Lalvani FMedSci Chair of Infectious Diseases Department of Respiratory Medicine National
More informationStrong purified protein derivative responses are associated with poor mycobacterium inhibition in latent TB
Eur Respir J 2010; 36: 348 354 DOI: 10.1183/09031936.00063209 CopyrightßERS 2010 Strong purified protein derivative responses are associated with poor mycobacterium inhibition in latent TB J.S.L. Kang,
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationDownloaded from:
Hill, PC; Brookes, RH; Fox, A; Jackson-Sillah, D; Jeffries, DJ; Lugos, MD; Donkor, SA; Adetifa, IM; de Jong, BC; Aiken, AM; Adegbola, RA; McAdam, KP (2007) Longitudinal assessment of an ELISPOT test for
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More information